NEW YORK, July 29, 2022 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP (www.kaplanfox.com) is investigating claims on behalf of investors of Enochian Biosciences, Inc. (NASDAQ: ENOB). A complaint has been filed on behalf of purchasers of Enochian securities between September 24, 2020 and May 31, 2022.
Enochian Biosciences is a biopharmaceutical company that focuses on identifying, developing, manufacturing and commercializing gene-modified cell therapy. On May 25, 2022, the U.S. Department of Justice announced that Serhat Gumrukcu, the co-founder of the Company had been arrested and charged in a murder-for-hire conspiracy. Following this news, the price of Enochian stock declined by over 36%. Previously Dr. Gumrukcu sold 253,493 shares of Enochian Biosciences stock on May 18, 2022, for over $2 million.
On July 1, 2022, the Company disclosed that it had discovered that former scientific advisor Serhat Gumrukcu altered two different sets of animal data generated by third-party research institutions. The Company also announced that it is evaluating its internal controls regarding the review and verification of external scientific data.
If you are a member of the proposed Class, you may move the court no later than September 26, 2022 to serve as a lead plaintiff for the purported class. You need not seek to become a lead plaintiff in order to share in any possible recovery. If you would like to discuss the complaint or our investigation, please contact us by emailing jcampisi@kaplanfox.com or by calling (212) 687-1980.
Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey. With over 35 years of experience in complex litigation Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
If you have any questions about this Notice, your rights, or your interests, please contact:
Frederic S. Fox
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(646) 315-9003
E-mail: ffox@kaplanfox.com
Laurence D. King
KAPLAN FOX & KILSHEIMER LLP
1999 Harrison Street, Suite 1560
Oakland, California 94612
(415) 772-4704
Fax: (415) 772-4707
E-mail: lking@kaplanfox.com
